trending Market Intelligence /marketintelligence/en/news-insights/trending/W0_fmb7WTyxqaPk1_J5yDQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Taiwan Leader Biotech H2 loss widens YOY

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

BLOG

Investment Banking Essentials Newsletter: June Edition

BLOG

Banking Essentials Newsletter: June Edition

Case Study

กรณีศึกษา A Bank Takes its Project Finance Assessments to a New Level


Taiwan Leader Biotech H2 loss widens YOY

Taiwan Leader Biotech Corp. said its second-half normalized net income amounted to a loss of NT$1.10 per share, compared with a loss of 56 cents per share in the prior-year period.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of NT$36.5 million, compared with a loss of NT$15.8 million in the year-earlier period.

Total revenue grew 32.5% on an annual basis to NT$9.6 million from NT$7.2 million, and total operating expenses grew on an annual basis to NT$67.7 million from NT$32.2 million.

Reported net income came to a loss of NT$58.6 million, or a loss of NT$1.76 per share, compared to a loss of NT$24.6 million, or a loss of 87 cents per share, in the year-earlier period.

For the year, the company's normalized net income totaled a loss of NT$1.68 per share, compared with a loss of NT$1.20 per share in the prior year.

Normalized net income was a loss of NT$54.0 million, compared with a loss of NT$33.6 million in the prior year.

Full-year total revenue grew 44.7% on an annual basis to NT$19.3 million from NT$13.3 million, and total operating expenses increased 59.7% year over year to NT$105.3 million from NT$66.0 million.

The company said reported net income totaled a loss of NT$86.6 million, or a loss of NT$2.69 per share, in the full year, compared with a loss of NT$53.1 million, or a loss of NT$1.90 per share, the prior year.

As of Feb. 15, US$1 was equivalent to NT$33.16.